NASDAQ:CRTX Cortexyme (CRTX) Stock Price, News & Analysis → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free CRTX Stock Alerts $1.95 +0.05 (+2.63%) (As of 07/29/2022) Add Compare Share Share Today's Range$1.86▼$1.9750-Day Range$0.82▼$1.9552-Week Range$1.78▼$40.66Volume272,200 shsAverage Volume620,672 shsMarket Capitalization$58.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cortexyme alerts: Email Address Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Cortexyme Stock (NASDAQ:CRTX)Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Read More CRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRTX Stock News HeadlinesAugust 1, 2022 | marketscreener.comCortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.comJuly 27, 2022 | marketscreener.comCortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.comJuly 27, 2022 | businesswire.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business WireJuly 27, 2022 | businesswire.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business WireJuly 27, 2022 | marketscreener.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.comJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo FinanceJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588July 27, 2022 | finance.yahoo.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022July 22, 2022 | streetinsider.comCortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.comJune 26, 2022 | gurufocus.comBragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.comJune 21, 2022 | benzinga.comCortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - BenzingaJune 21, 2022 | nasdaq.comCortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - NasdaqJune 21, 2022 | finance.yahoo.comCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsJune 13, 2022 | businesswire.comCortexyme Appoints June Bray to its Board of Directors - Business WireJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of Directors - Yahoo FinanceJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of DirectorsJune 11, 2022 | marketscreener.comCortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.comJune 10, 2022 | marketscreener.comCortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comMay 22, 2022 | businesswire.comCortexyme Successfully Completes Acquisition of Novosteo - Business WireMay 20, 2022 | nasdaq.comThis Is the Worst Type of Credit Card for Most Consumers - NasdaqMay 20, 2022 | finance.yahoo.comPPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo FinanceMay 20, 2022 | marketscreener.comCortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.comMay 20, 2022 | finance.yahoo.comCortexyme Successfully Completes Acquisition of Novosteo - Yahoo FinanceMay 20, 2022 | finance.yahoo.comCortexyme Appoints Dr. Philip Low to Its Board of DirectorsMay 13, 2022 | nasdaq.comPre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - NasdaqSee More Headlines Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2021Today6/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryHealth Care Technology Current SymbolNASDAQ:CRTX CUSIP21924P10 CIK1145404 Webwww.cortexyme.com Phone(650) 910-5717FaxN/AEmployees55Year Founded2012Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.96% Return on Assets-63.53% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.20Miscellaneous Outstanding Shares30,151,000Free Float21,739,000Market Cap$23.82 million OptionableNot Optionable Beta1.40 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Leslie J. Holsinger Ph.D. (Age 57)Exec. VP of R&D Comp: $603.85kDr. Dirk Thye M.D. (Age 52)CEO & Director Mr. Ted Monohon (Age 56)VP of Fin., Principal Financial Officer & Chief Accounting Officer Mr. Brendan Hannah M.B.A.Chief Bus. OfficerDr. Karen L. Smith L.L.M (Age 54)L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer Key CompetitorsSangamo TherapeuticsNASDAQ:SGMOAdverum BiotechnologiesNASDAQ:ADVMCoherus BioSciencesNASDAQ:CHRSScholar RockNASDAQ:SRRKForma TherapeuticsNASDAQ:FMTXView All Competitors CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed in 2024? Cortexyme's stock was trading at $1.05 at the start of the year. Since then, CRTX stock has increased by 85.7% and is now trading at $1.95. View the best growth stocks for 2024 here. How were Cortexyme's earnings last quarter? Cortexyme, Inc. (NASDAQ:CRTX) posted its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.05. What other stocks do shareholders of Cortexyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS). When did Cortexyme IPO? Cortexyme (CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. How do I buy shares of Cortexyme? Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRTX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.